Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges / 中华医学杂志(英文版)
Chinese Medical Journal
;
(24): 1908-1919, 2021.
Artigo
em Inglês
| WPRIM
| ID: wpr-887633
ABSTRACT
Immunotherapy has dramatically altered the treatment of non-small cell lung cancer. Currently, the emergence of combination strategies in immunotherapy has brightened the prospects of improved clinical outcomes and manageable safety profiles in the first/second-line settings. However, sub-optimal response rates are still observed in several clinical trials. Hence, alternative combination models and candidate selection strategies need to be explored. Herein, we have critically reviewed and commented on the published data from several clinical trials, including combined immunotherapy and chemotherapy, anti-angiogenic agents, epidermal growth factor receptor/anaplastic lymphoma kinase tyrosine kinase inhibitors, radiotherapy, and other immune checkpoint inhibitors.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Inibidores da Angiogênese
/
Inibidores de Proteínas Quinases
/
Imunoterapia
/
Neoplasias Pulmonares
Tipo de estudo:
Estudo prognóstico
Limite:
Humanos
Idioma:
Inglês
Revista:
Chinese Medical Journal
Ano de publicação:
2021
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS